OncoSec Medical to Present at Two Events in February
SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it will present at two high-profile scientific and investment conferences in February.
BIO CEO & Investor Conference
Punit Dhillon, President and CEO, will present a corporate overview at the 17th Annual BIO CEO & Investor Conference, on February 9-10, 2015 in New York City, NY. The presentation is scheduled to begin at 9:30 AM ET on Monday, February 9 in the Duke of Windsor room.
At the time of the presentation, a live webcast will be available via the following link: http://www.veracast.com/webcasts/bio/ceoinvestor2015/43106259832.cfm
OncoSec recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. After the presentation, an archived version of the webcast will be available for 90 days in the “Events” section of the OncoSec web page at http://www.oncosec.com.
Each year, the BIO CEO & Investor Conference provides a forum for institutional investors, industry analysts, and senior biotechnology executives to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities. For more information, visit: https://www.bio.org/events/conferences/bio-ceo-investor-conference
Molecular Medicine Tri-Conference 2015
Robert H. Pierce, MD, Chief Scientific Officer, will present at Cambridge Healthtech Institute’s 22nd International Molecular Medicine Tri-Conference, on February 15-20, 2015 at Moscone North Convention Center in San Francisco, CA. Dr. Pierce’s lecture, “Translational Approaches for the Development of Intratumoral Immunotherapies,” is scheduled to begin at 11:15 AM PT on Tuesday, February 17.
The 22nd International Molecular Medicine Tri-Conference is the industry's preeminent event on molecular medicine, focusing on drug discovery, genomics, diagnostics and information technology. Spanning six days this year, the Tri-Conference includes an expanded program that includes six symposia, over 20 short courses, and 17 conference programs. For more information, please visit: http://www.triconference.com.
About OncoSec Medical
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Source: OncoSec Medical Inc.
Released February 3, 2015